• Written by ajiang
  • November 18, 2010 at 6:14 pm
  • Panel Discussions led by world-renowned experts of investors and clinicians, offering insights to different categories in specific healthcare sectors. (subject to change)

    Tuesday, January 11th, 2011

    Session 1 – Diagnostics & Personalized Medicine: Advances in molecular biology now make it possible to detect diseases sooner, allowing physicians to advise patients on optimal therapies. This panel explores the changing world of diagnostics, bringing together executives, experienced venture capitalists, and a physician. Together they will explore the product areas and business models that have made diagnostics a hot area for investors today. Along the way, panelists will discuss new technologies of interest to consolidators and address the challenges start-ups face in commercializing these game-changing products.


    Session 2 – Neurology: Technological advances continue to give hope that new medical devices will improve the quality of life for people with neurological conditions such as epilepsy or Parkinsons’ Disease. There is also hope that these advances will stimulate better recovery for patients with neurological damage from traumatic events ranging from ischemic stroke to spinal cord injury. This panel, comprised of leading strategic/venture investors and industry veterans, will explore the most appealing therapeutic areas and technologies for investment in 2011. Panelists will discuss what it takes for a neurology-related company to succeed in today’s challenging economic and regulatory climate.

    Denise Barbut, MD, Founder Benechill
    Frank Fischer, President, Neuropace, Inc.
    Mike Henson, General Partner, Medfocus Fund
    Jeff Erb, Director Business Development, Medtronic

    Session 3 – Urology and Womens Care: Urology and Women’s health have been areas of substantial M&A activity during the last 10 years as the major medtech consolidators have been busy building separate business units to address these medical needs. This panel includes representatives from several large medtech acquirers, as well as venture and private equity firms with major investments in this field. The panelists will explore exciting new products under development and the issues facing this dynamic market.

    Jessica Grossman MD, Ethicon
    Jan Garfinkle, Managing Partner, Arboretum Ventures
    Ben Daverman, Partner, GTCR Golder Rauner
    David Amerson, Global Vice President Coloplast Surgical Urology
    Don Haut, Senior Vice President, Smith & Nephew

    Wednesday, January 12th, 2011

    Session 1 – Cardiology: Advances in structural heart repair/replacement, cardiac rhythm management, interventional techniques, cell replacement and regeneration therapies continue to refine one of the most successful areas of modern medicine: cardiac care. This panel of highly experienced medical and business professionals will describe what important products are on the horizon, and how these products will fare in a post healthcare – reform world.

    Frank Litvack, Former President, Conor
    Tao Forcht Dagi, MD, Partner, HLM Ventures
    David Milne, Partner, SV LifeSciences
    Michael Buck, Director Business Development, Abbott Ventures

    Session 2 – Orthopedics: The orthopedic market include joint reconstruction, spine, trauma fixation, arthroscopy and biologics. Growth in each of these sectors is being driven by an aging US population. Today there are a large number of very innovative solutions in development which should offer the large orthopedic companies an opportunity to grow rapidly during the coming years. Join our panel of experts to explore the products in development and the interest and needs of the potential acquirers.

    Bryan Hughes, Director, P & M Corporate Finance
    Nancy Lynch, MD
    John Barrett, CEO, CoAlign Surgical
    Richard Ferrari, Partner, DeNovo Ventures
    Karen Talmadge, Vice President Medtronic Inc.

    Session 3 – Oncology: Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer. These advanced products include advanced cancer screening and imaging technologies, infusion of therapeutic materials directly into a tumor’s blood vessel, radiotherapy to treat solid tumors throughout the body more accurately and less invasively, as well as stem cell and antibody treatments to fight malignancies. This panel will discuss new products in development, their impact on patient care and the interest of medtech consolidators in these advanced therapies.

    Scott Schalk, Managing Director, Dawson James
    Daniel Kraft, MD
    Euan Thompson, CEO, Accuray
    Norm Weldon, Investor
    Tom Umbel, Vice President, Hologic

  • Conference Info:


    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City

    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!